Roche's com­bo ther­a­py re­duces risk of liv­er can­cer re­turn­ing but rais­es safe­ty ques­tions: #AACR23

OR­LAN­DO — Roche’s Tecen­triq-Avastin com­bi­na­tion, al­ready ap­proved for one in­di­ca­tion, re­duced the risk of can­cer re­cur­rence among pa­tients af­ter they re­ceived surgery for an ear­ly-stage liv­er …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER